Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer - PubMed (original) (raw)
Clinical Trial
. 2010 Jun 3;362(22):2053-65.
doi: 10.1056/NEJMoa0909638.
Jong-Hyeon Jeong, Charles E Geyer Jr, Joseph P Costantino, Eduardo R Pajon, Louis Fehrenbacher, James N Atkins, Jonathan Polikoff, Victor G Vogel, John K Erban, Priya Rastogi, Robert B Livingston, Edith A Perez, Eleftherios P Mamounas, Stephanie R Land, Patricia A Ganz, Norman Wolmark
Affiliations
- PMID: 20519679
- PMCID: PMC2935316
- DOI: 10.1056/NEJMoa0909638
Clinical Trial
Longer therapy, iatrogenic amenorrhea, and survival in early breast cancer
Sandra M Swain et al. N Engl J Med. 2010.
Abstract
Background: Chemotherapy regimens that combine anthracyclines and taxanes result in improved disease-free and overall survival among women with operable lymph-node-positive breast cancer. The effectiveness of concurrent versus sequential regimens is not known.
Methods: We randomly assigned 5351 patients with operable, node-positive, early-stage breast cancer to receive four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel (sequential ACT); four cycles of doxorubicin and docetaxel (doxorubicin-docetaxel); or four cycles of doxorubicin, cyclophosphamide, and docetaxel (concurrent ACT). The primary aims were to examine whether concurrent ACT was more effective than sequential ACT and whether the doxorubicin-docetaxel regimen would be as effective as the concurrent-ACT regimen. The secondary aims were to assess toxic effects and to correlate amenorrhea with outcomes in premenopausal women.
Results: At a median follow-up of 73 months, overall survival was improved in the sequential-ACT group (8-year overall survival, 83%) as compared with the doxorubicin-docetaxel group (overall survival, 79%; hazard ratio for death, 0.83; P=0.03) and the concurrent-ACT group (overall survival, 79%; hazard ratio, 0.86; P=0.09). Disease-free survival was improved in the sequential-ACT group (8-year disease-free survival, 74%) as compared with the doxorubicin-docetaxel group (disease-free survival, 69%; hazard ratio for recurrence, a second malignant condition, or death, 0.80; P=0.001) and the concurrent-ACT group (disease-free survival, 69%; hazard ratio, 0.83; P=0.01). The doxorubicin-docetaxel regimen showed noninferiority to the concurrent-ACT regimen for overall survival (hazard ratio, 0.96; 95% confidence interval, 0.82 to 1.14). Overall survival was improved in patients with amenorrhea for 6 months or more across all treatment groups, independently of estrogen-receptor status.
Conclusions: Sequential ACT improved disease-free survival as compared with doxorubicin-docetaxel or concurrent ACT, and it improved overall survival as compared with doxorubicin-docetaxel. Amenorrhea was associated with improved survival regardless of the treatment and estrogen-receptor status. (ClinicalTrials.gov number, NCT00003782.)
2010 Massachusetts Medical Society
Figures
Figure 1
Enrollment, Randomization, and Follow-up of Study Participants.
Figure 2. Overall Survival and Disease-free Survival
Panels A and B show the Kaplan–Meier estimates of survival and disease-free survival in the three treatment groups over the follow-up period. P values are by two-sided log-rank tests. At the prespecified significance level of 0.05, a significant improvement in overall survival was associated with doxorubicin and cyclophosphamide followed by docetaxel (sequential ACT) as compared with doxorubicin–docetaxel (P = 0.03), and a marginal benefit was associated with sequential ACT over concurrent administration of doxorubicin, docetaxel, and cyclophosphamide (concurrent ACT) (P = 0.09) (Panel A). There was a statistically significant decrease in disease recurrence, a second malignant condition, or death in the sequential-ACT group as compared with the concurrent-ACT group (P = 0.01). In addition, the rate of disease-free survival was significantly higher among patients in the sequential-ACT group than among patients in the doxorubicin–docetaxel group (P = 0.001) (Panel B). Panels C and D show the effect of amenorrhea on overall survival and disease-free survival, respectively, for the combined treatment groups adjusted for treatment, estrogen-receptor status, age, lymph-node status, tumor size, and use or nonuse of hormone therapy. Overall survival (hazard ratio for death, 0.76; P = 0.04) and disease-free survival (hazard ratio for disease recurrence, a second malignant condition, or death, 0.70; P<0.001) were improved among patients with amenorrhea for 6 months or more.
Figure 3. Hazard Ratios for Various Subgroups, According to Treatment
Panel A shows the reduced risk of death associated with doxorubicin and cyclophosphamide followed by docetaxel (sequential ACT) as compared with concurrent administration of all three agents (concurrent ACT). Panel B shows the reduced risk of disease recurrence, a second malignant condition, or death associated with sequential ACT as compared with concurrent ACT. Panel C shows the reduced risk of death associated with sequential ACT as compared with doxorubicin–docetaxel. Panel D shows the reduced risk of disease recurrence, a second malignant condition, or death associated with sequential ACT as compared with doxorubicin–docetaxel. Panels E and F show data from the menstrual-history study. Panel E shows the risk of death according to subgroups, adjusted for lymph-node status and tumor size. Panel F shows the risk of disease recurrence, a second malignant condition, or death according to subgroups, adjusted for lymph-node status and tumor size. The size of the squares is proportional to the size of the subgroups. CI denotes confidence interval, and ER estrogen receptor.
Figure 3. Hazard Ratios for Various Subgroups, According to Treatment
Panel A shows the reduced risk of death associated with doxorubicin and cyclophosphamide followed by docetaxel (sequential ACT) as compared with concurrent administration of all three agents (concurrent ACT). Panel B shows the reduced risk of disease recurrence, a second malignant condition, or death associated with sequential ACT as compared with concurrent ACT. Panel C shows the reduced risk of death associated with sequential ACT as compared with doxorubicin–docetaxel. Panel D shows the reduced risk of disease recurrence, a second malignant condition, or death associated with sequential ACT as compared with doxorubicin–docetaxel. Panels E and F show data from the menstrual-history study. Panel E shows the risk of death according to subgroups, adjusted for lymph-node status and tumor size. Panel F shows the risk of disease recurrence, a second malignant condition, or death according to subgroups, adjusted for lymph-node status and tumor size. The size of the squares is proportional to the size of the subgroups. CI denotes confidence interval, and ER estrogen receptor.
Comment in
- Taxane-based chemotherapy for node-positive breast cancer--take-home lessons.
Ellis M. Ellis M. N Engl J Med. 2010 Jun 3;362(22):2122-4. doi: 10.1056/NEJMe1003854. N Engl J Med. 2010. PMID: 20519684 No abstract available. - Duration of chemotherapy for early stage breast cancer: have we reached the limit? What is the survival impact of amenorrhea?
Hirsh RL, Fox KR. Hirsh RL, et al. Curr Treat Options Oncol. 2010 Dec;11(3-4):59-62. doi: 10.1007/s11864-010-0123-3. Curr Treat Options Oncol. 2010. PMID: 21061193 No abstract available. - Amenorrhea from breast cancer therapy--not a matter of dose.
Swain SM, Jeong JH, Wolmark N. Swain SM, et al. N Engl J Med. 2010 Dec 2;363(23):2268-70. doi: 10.1056/NEJMc1009616. N Engl J Med. 2010. PMID: 21121855 No abstract available.
Similar articles
- Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P, Crown J, Di Leo A, Buyse M, Balil A, Andersson M, Nordenskjöld B, Lang I, Jakesz R, Vorobiof D, Gutiérrez J, van Hazel G, Dolci S, Jamin S, Bendahmane B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Piccart-Gebhart M; BIG 02-98 Collaborative Group. Francis P, et al. J Natl Cancer Inst. 2008 Jan 16;100(2):121-33. doi: 10.1093/jnci/djm287. Epub 2008 Jan 8. J Natl Cancer Inst. 2008. PMID: 18182617 Clinical Trial. - Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197.
Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Goldstein LJ, et al. J Clin Oncol. 2008 Sep 1;26(25):4092-9. doi: 10.1200/JCO.2008.16.7841. Epub 2008 Aug 4. J Clin Oncol. 2008. PMID: 18678836 Free PMC article. Clinical Trial. - Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.
Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA. Swain SM, et al. Breast Cancer Res Treat. 2009 Jan;113(2):315-20. doi: 10.1007/s10549-008-9937-0. Epub 2008 Feb 27. Breast Cancer Res Treat. 2009. PMID: 18302020 Free PMC article. Clinical Trial. - Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?
Perez EA. Perez EA. Curr Oncol Rep. 2003 Jan;5(1):66-71. doi: 10.1007/s11912-003-0089-4. Curr Oncol Rep. 2003. PMID: 12493153 Review. - Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T, Le Du F, Xiao L, Kogawa T, Barcenas CH, Alvarez RH, Valero V, Shen Y, Ueno NT. Fujii T, et al. JAMA Oncol. 2015 Dec;1(9):1311-8. doi: 10.1001/jamaoncol.2015.3062. JAMA Oncol. 2015. PMID: 26402167 Free PMC article. Review.
Cited by
- Development of a Web-Based Interactive Tool for Visualizing Breast Cancer Clinical Trial Tolerability Data.
Luu M, Gresham G, Henry L, Kim S, Rogatko A, Yothers G, Hays RD, Tighiouart M, Ganz PA. Luu M, et al. JCO Clin Cancer Inform. 2024 Jul;8:e2400007. doi: 10.1200/CCI.24.00007. JCO Clin Cancer Inform. 2024. PMID: 39013121 Free PMC article. - Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial.
Chen Y, Li WX, Wu JH, Chen GH, Yang CM, Lu H, Wang X, Wang SS, Huang H, Cai L, Zhao L, Peng RJ, Lin Y, Tang J, Zeng J, Zhang LH, Ke YL, Wang XM, Liu XM, Zhang AQ, Xu F, Bi XW, Huang JJ, Li JB, Pang DM, Xue C, Shi YX, He ZY, Lin HX, An X, Xia W, Cao Y, Guo Y, Hong RX, Jiang KK, Zhong YY, Zhang G, Tienchaiananda P, Oikawa M, Yuan ZY, Chen QJ. Chen Y, et al. Breast Cancer (Dove Med Press). 2024 Apr 12;16:223-231. doi: 10.2147/BCTT.S447290. eCollection 2024. Breast Cancer (Dove Med Press). 2024. PMID: 38628818 Free PMC article. Clinical Trial. - Current perspectives and trends in nanoparticle drug delivery systems in breast cancer: bibliometric analysis and review.
Sun S, Wang YH, Gao X, Wang HY, Zhang L, Wang N, Li CM, Xiong SQ. Sun S, et al. Front Bioeng Biotechnol. 2023 Sep 12;11:1253048. doi: 10.3389/fbioe.2023.1253048. eCollection 2023. Front Bioeng Biotechnol. 2023. PMID: 37771575 Free PMC article. - Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer - Controversies and Standards in Healthcare.
Müller V, Fasching PA, Nabieva N, Fehm TN, Thill M, Schmidt M, Kühn T, Banys-Paluchowski M, Belleville E, Juhasz-Böss I, Untch M, Kolberg HC, Harbeck N, Aktas B, Stickeler E, Kreuzeder J, Hartkopf AD, Janni W, Ditsch N. Müller V, et al. Geburtshilfe Frauenheilkd. 2023 May 23;83(6):673-685. doi: 10.1055/a-2073-1887. eCollection 2023 Jun. Geburtshilfe Frauenheilkd. 2023. PMID: 37614683 Free PMC article.
References
- Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687–717. - PubMed
- Nabholtz JM, Falkson C, Campos D, et al. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol. 2003;21:968–75. [Erratum, J Clin Oncol 2003;21:2048.] - PubMed
- Mackey JR, Paterson A, Dirix LY, et al. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy (CT) for patients (pts) with metastatic breast cancer (MBC) Proc Am Soc Clin Oncol. 2002;21:35a. abstract.
- Knobf MT. The influence of endocrine effects of adjuvant therapy on quality of life outcomes in younger breast cancer survivors. Oncologist. 2006;11:96–110. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U10-CA-69651/CA/NCI NIH HHS/United States
- U10 CA025224-25/CA/NCI NIH HHS/United States
- N01 CA032102/CA/NCI NIH HHS/United States
- N01 CA013612/CA/NCI NIH HHS/United States
- U10 CA058348-10/CA/NCI NIH HHS/United States
- CA-25224/CA/NCI NIH HHS/United States
- CA-45808/CA/NCI NIH HHS/United States
- U10 CA037377/CA/NCI NIH HHS/United States
- CA07190/CA/NCI NIH HHS/United States
- U10 CA069974-10/CA/NCI NIH HHS/United States
- U10-CA-37377/CA/NCI NIH HHS/United States
- U10 CA045808-22/CA/NCI NIH HHS/United States
- U10 CA045808/CA/NCI NIH HHS/United States
- U10 CA012027/CA/NCI NIH HHS/United States
- U10 CA013612/CA/NCI NIH HHS/United States
- U10-CA-69974/CA/NCI NIH HHS/United States
- CA-58348/CA/NCI NIH HHS/United States
- U10-CA-12027/CA/NCI NIH HHS/United States
- CA2115/CA/NCI NIH HHS/United States
- CA-13612/CA/NCI NIH HHS/United States
- CA-32102/CA/NCI NIH HHS/United States
- U10 CA069651/CA/NCI NIH HHS/United States
- U10 CA032102/CA/NCI NIH HHS/United States
- U10 CA069974/CA/NCI NIH HHS/United States
- U10 CA012027-35/CA/NCI NIH HHS/United States
- U10 CA007190/CA/NCI NIH HHS/United States
- U10 CA069651-09/CA/NCI NIH HHS/United States
- U10 CA013612-35/CA/NCI NIH HHS/United States
- U10 CA025224/CA/NCI NIH HHS/United States
- U10 CA032102-30/CA/NCI NIH HHS/United States
- U10 CA058348/CA/NCI NIH HHS/United States
- U10 CA037377-18/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical